Google's Verily to collect health data from 10,000 for long-range study

Cara Livernois | | Health Exec | Precision Medicine

Verily, formerly Google Life Sciences, plans on enrolling 10,000 participants in a study incorporating the latest technology for data collection on how individuals can lead their healthiest lives.

Set to begin at Stanford University and Duke University, the study utilizes the Verily’s Study Watch wearable to collect data on electrocardiograms (ECG), heart rate, electrodermal activity, inertial movements and sleep. Spanning up to five years, the study will collect large amounts of data to examine what exactly makes a healthy human.

"No one has attempted this deep a dive into so many individuals over so long a time," said Sam Gambhir, chair of the department of radiology at Stanford.

Read the full story by clicking the link below:

Google Offshoot Starts A 10,000-Person Study To Plumb Human Biology

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.